Wall Street Zen Upgrades Greenland Mines Ltd. Common Stock (NASDAQ:GRML) to “Sell”

Greenland Mines Ltd. Common Stock (NASDAQ:GRML) was upgraded by research analysts at Wall Street Zen to a “sell” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings upgraded shares of Greenland Mines Ltd. Common Stock from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 25th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Greenland Mines Ltd. Common Stock Price Performance

GRML opened at $4.88 on Friday. The stock’s 50 day simple moving average is $10.26 and its 200 day simple moving average is $17.42. Greenland Mines Ltd. Common Stock has a 1 year low of $4.37 and a 1 year high of $36.99. The firm has a market cap of $15.52 million, a price-to-earnings ratio of -15.25 and a beta of 7.13.

Greenland Mines Ltd. Common Stock (NASDAQ:GRML) last announced its quarterly earnings data on Monday, August 17th. The company reported ($0.03) earnings per share for the quarter.

Insider Transactions at Greenland Mines Ltd. Common Stock

In related news, Director Riad Hussein El-Dada sold 3,500 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $11.50, for a total transaction of $40,250.00. Following the completion of the transaction, the director owned 3,500 shares in the company, valued at $40,250. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Jeff Leblanc purchased 14,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The stock was bought at an average price of $9.72 per share, for a total transaction of $136,080.00. Following the acquisition, the chief financial officer owned 110,406 shares of the company’s stock, valued at $1,073,146.32. This represents a 14.52% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 11.30% of the company’s stock.

Hedge Funds Weigh In On Greenland Mines Ltd. Common Stock

Several hedge funds and other institutional investors have recently modified their holdings of GRML. Jane Street Group LLC bought a new position in Greenland Mines Ltd. Common Stock in the second quarter worth about $26,000. Brummer Multi Strategy AB purchased a new position in shares of Greenland Mines Ltd. Common Stock during the 4th quarter worth approximately $175,000. Geode Capital Management LLC grew its holdings in shares of Greenland Mines Ltd. Common Stock by 51.8% during the 4th quarter. Geode Capital Management LLC now owns 491,832 shares of the company’s stock worth $142,000 after acquiring an additional 167,905 shares during the period. Renaissance Technologies LLC bought a new position in shares of Greenland Mines Ltd. Common Stock in the 4th quarter worth approximately $126,000. Finally, XTX Topco Ltd lifted its stake in shares of Greenland Mines Ltd. Common Stock by 101.2% in the 4th quarter. XTX Topco Ltd now owns 160,569 shares of the company’s stock valued at $46,000 after purchasing an additional 80,768 shares during the period. Hedge funds and other institutional investors own 20.07% of the company’s stock.

Greenland Mines Ltd. Common Stock Company Profile

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases – cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.